Business
Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board
Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\n Baton Rouge, LA, March 21, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) (\"Adhera\" or the \"Company\"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Jean Buteau, PhD., to the Company’s Scientific Advisory Board. Dr. Buteau, a published scientist, and award-winning pioneer in the field of diabetes, will lend his expertise and oversight to help advance Adhera’s pipeline, including MLR-1023, the Company’s Phase 2-ready drug candidate as a novel therapeutic for treating Type 1 diabetes (T1D). MLR-1023 is a next generation, non-PPAR insulin sensitizer via lyn kinase activation that has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and 2b diabetes studies. Dr. Buteau has a deep understanding of the mechanism of action of MLR-1023 through his research proving the potent effect of MLR-1023 to have influence on pancreatic beta cell protection and proliferation in vitro and in mouse models of T1D, which is theorized to potentially translate to delaying or preventing T1D in humans. A new effective, safe treatment would be a major leap forward for a disease affecting approximately 9 million people worldwide,1 including more than 2 million people in North America2,3 that rely upon insulin injections to manage their disease. Dr. Buteau’s groundbreaking work has earned him numerous accolades and funding awards supporting additional laboratory and clinical research. These include, but are not limited to, grants from the Alberta Diabetes Institute, DRIFCan, Defeating Diabetes, Shastri Indo-Canada Institute, Canada Foundation for Innovation, Canadian Institutes of Health Research, and Natural Science and Engineering Research Council. Interested parties are strongly encouraged to view two short videos from November 2020 and June 2021 highlighting the potential of MLR-1023 and the accomplishments of Dr. Buteau and his lab in the field of diabetes at: https://www.youtube.com/watch?app=desktop&v=BDaKbJ58E54 and https://www.youtube.com/watch?v=rdY0C3F_Ke0 “I feel we are on the edge of a breakthrough that can revolutionize diabetes care and greatly improve the quality of life for millions of T1D patients today and for generations to come,” commented Dr. Buteau. “I am thrilled that Adhera sees the op...